Chapter 101 Cooperation with Novartis (4K)

The three people present were stunned for a moment and couldn't help but look at each other.

There is nothing wrong with what Friedman, a Jew, said. High sugar, obesity, and alcohol are already the daily routine of every ordinary American!

Because of this, the United States has become the country with the fastest growing rate of fatty liver disease in the world in the past decade, and is also the country with the most cirrhosis caused by non-viral hepatitis!

But soon, Klein reacted.

"What you said, Friedman, is indeed correct, but all this depends on whether Tsingshan Pharmaceuticals can really develop a drug that is effective for liver regeneration."

"As far as I know, Gilead is also developing Similar regenerative agents, but the effect is not very good, and it has been stuck in the second phase of clinical trials without making much progress.”

Friedman didn’t care about Klein’s rebuttal. He shrugged and said with a bit of confidence:

“This Chinese pharmaceutical company is different from Gilead. They have developed a cure. Hepatitis B's 'Acofenprovir', but what about Gilead? "

"No."

"So, in my opinion, Tsingshan Pharmaceutical's R&D capabilities in the field of liver diseases are not necessarily worse than Gilead, and may even surpass Gilead."

"And, the most important thing is..." 
He paused deliberately:

“Whether it’s Gilead or Pfizer you mentioned just now, if they develop a ‘liver regeneration activator’, will we have a chance to cooperate? Can we get a share of the pie?”

“Impossible.”

"And Qingshan Pharmaceutical will be our only chance to take a share of such a large liver disease market."

After finishing his words, Klein swallowed all the rebuttals he had been feeling. At this moment, it was truly I understand what Friedman meant.

Indeed, although Novartis is a global pharmaceutical giant, top pharmaceutical companies actually have their own areas of business research and development.

For example, Gilead focuses on liver disease, AIDS and various infectious diseases. Its company’s star products are mainly in liver disease and AIDS drugs.

Pfizer, for example, specializes in 13-valent pneumonia vaccine, antibiotics (azithromycin), and breast cancer targeted drugs, so its main core competitiveness also comes from these disease sectors.

Similarly, Novartis’ star products are drugs for cardiovascular and cerebrovascular diseases and leukemia, but there are almost no products that can compete in other disease markets.

In other words,

each major pharmaceutical company has its own core areas, and it is very difficult for Novartis to enter markets that are not its core areas.

After Gilead and Pfizer develop core drugs, will Novartis have the opportunity to cooperate?

No!

Only Tsingshan Pharmaceutical has excellent R&D capabilities and is a Chinese pharmaceutical company. They must rely on local American pharmaceutical companies to enter the U.S. market!

This gives Novartis an opportunity to take a share of the liver disease market!

Thinking of this, President Green couldn't help but change his sitting posture slightly and looked at Friedman with interest.

"Friedman, I admit that what you said moved me."

"But do we need to be so anxious? After all, they haven't even started the first phase of clinical trials. ”

"It is necessary! It is very necessary!"

Friedman replied firmly:

"Mr. President, it will be too late to talk after they reach the second clinical phase."

“You can think about it, once they show it in clinical trials With the good 'liver regeneration effect', how many pharmaceutical companies will come to seek cooperation?"

"The situation we face will not be as easy as it is now, and we may have to pay more than we do now. Ten times the price.”

"Furthermore, through some personal relationships, I learned about Fuxing Pharmaceutical and GlaxoSmithKline, which have agency cooperation with Tsingshan Pharmaceutical. They both told me that

Zhang Yang, the boss of Qingshan Pharmaceutical, seems to be more willing to use ordinary agency way to sign the contract, rather than the BD milestone transaction model that is common in the market now."

"So... this is contrary to us. It's a good thing, we only need to negotiate a priority agency contract with them, and we can get the priority agency rights without even paying additional buyout fees."

"Once their new drug is really effective and passes clinical trials. In the future, we can make a lot of money!

Even if we fail... we will only lose some energy.”

The last sentence completely moved the three people present.

President Green glanced at Friedman appreciatively, and I have to say that this comes from the shrewdness of the Jews.

While everyone was waiting to see and wait for the second phase clinical results of Tsingshan Pharmaceuticals to come out before making a decision, Friedman was already keenly aware of the huge information gap and thought of doing something to his own side. Said in the best possible way.

"Okay, Friedman, you convinced me."

As he said that, he looked at Klein and Coles, who also nodded.

"Since everyone agrees, I will ask the general manager of China District to contact Qingshan Pharmaceutical."

Before he finished speaking, Friedman shook his head:

"President Green, this I want to fly to Huaxia and talk to Qingshan Pharmaceutical in person."

"You? Go in person?"

Green was a little surprised, but then he nodded in agreement.

"Okay! Then I'll leave this matter to you."

......

Friedman was very efficient. The next night, he took a flight from New York. Plane to Magic City.

After a short rest, he appeared in Zhang Yang's office early on the fourth day.

“You mean, you want to introduce our ‘hepatocyte regeneration-promoting activating agent’ now and simultaneously conduct FDA clinical trials in the United States?”

Zhang Yang is still a little surprised by Friedman's arrival. Generally speaking, domestic innovative drugs first achieve good results in domestic clinical trials and then apply for clinical trials abroad.

For example, the previous "ITG human myelopoietin" and Hengrui Medicine's liver cancer targeted drug camrelizumab first achieved results domestically and then were promoted abroad.

Another option is to conduct clinical trials with the US FDA first.

This situation is mainly due to the high gold content of the FDA, which can be said to be the global benchmark for drug approval. As long as the FDA passes it, there is a high probability that other markets will also pass approval smoothly.

This is the first choice for companies that strive to become global giants.

Therefore, it is rare for both sides to proceed simultaneously.

"Yes, Mr. Zhang Yang."

Friedman said:

"To be precise, we are very optimistic about your company's 'hepatocyte-stimulating product' "Regeneration active agent', so we are willing to help your company launch FDA clinical trials in the United States."

"Of course, if it can eventually pass the third phase of clinical trials, we hope to obtain the U.S. market sales agency rights for this drug."

Help us?

Zhang Yang felt something was wrong. Why did this sound so awkward?

Gradually, he came back to his senses and corrected:

“President Friedman, I must correct you. It’s not that you helped us, so you should get the sales agent right in the US market. . ”

“But you want to get the agency, so you take the initiative to contact us. You are begging us.”

"Don't get this logic wrong."

After being exposed in person about his tricks, Friedman remained calm and shrugged:

"Is this important? ”

“Very important!”

Zhang Yang replied firmly.

In fact, this technique is very common in negotiations, and is generally used by the weak party to confuse logical relationships so that it can gain a certain initiative in the negotiation.

"Okay, Zhang." Friedman nodded, and then said again:

"Zhang, we are very optimistic about your company's 'promoting liver cell regeneration'" "Life Agent', we are willing to actively assist you in conducting FDA clinical trials."

"In exchange, we hope to obtain your company's sales agency rights for this drug in the U.S. market."

Zhang Yang nodded, this finally sounded like a fair deal.

After a moment, his mind started racing. The current actual situation of Qingshan Pharmaceutical is that it does not have the energy or connections to develop overseas markets, and can only rely on these traditional and established pharmaceutical companies.

Novartis is also one of the international giants. If they assist in the FDA's clinical trials, it will undoubtedly relieve Tsingshan Pharmaceutical of a huge burden.

Once the "activating agent for promoting liver cell regeneration" is clinically launched in the United States through FDA, it will not only gain huge benefits from the US market, but also bring huge benefits to its global promotion!

Thinking of this, he nodded slightly and already had a plan in mind.

"President Friedman, I am not opposed to reaching an agreement with your company."

"However, regarding the agency agreement, I prefer a simple agency model, and I will not conduct a BD milestone transaction."

Friedman smiled slightly. The boss of Qingshan Pharmaceutical in front of him, Zhang Yang, was indeed as fond of the traditional agency model as the legend said.

After a moment, he replied:

“No problem, we can accept the traditional agency model.”

"And I have already thought about it for you in advance. We can pre-sign a priority agency contract. After your company enters the third phase of clinical trials, we will discuss the agency price in detail."

"After all, we are talking about the price now. It’s too early.”

Zhang Yang nodded, he had the same idea.

“Okay, then there is one last question left.”

“I hope that Novartis will bear all the costs of our ‘hepatocellular activator’ in the FDA clinical trial.”

"?"

Friedman was stunned and showed a surprised expression.

After a few seconds, he said incredulously:

"Are we responsible?"

Without waiting for Zhang Yang to answer, he said urgently for the first time:

"Zhang, this is against the rules."

"We are assisting you in conducting FDA clinical trials. We can provide you with network resources and channel resources, and can help you contact clinical hospitals and recruit subjects, but The costs are borne by you.”
"What's going on with us? What we signed is just a traditional agency contract. We don't have any shares or dividends. We just assist!"

Zhang Yang shrugged:

"You Didn’t you already tell me that you got the agency contract?”

"Agency contract?"

Friedman suddenly became a little angry and said in a low voice:

"This agency contract must be effective after you pass the FDA's third clinical phase. If you pass the second clinical phase in a row, If you can’t make it through the deadline, then all the money will be wasted.”

Zhang Yang calmly said:

“If you think it’s risky, you can refuse.”

"I am not as eager to enter the U.S. market as you might think. Moreover, there are domestic pharmaceutical companies in China conducting FDA clinical trials in the U.S. If I pay, I can completely entrust them with help."

These words pierced Friedman's heart. This was also what he was most worried about.

Once Tsingshan Pharmaceuticals finds other channels to enter the FDA, Novartis will most likely miss out on this drug.

This is unacceptable to him.

After a while, he took a deep breath and whispered:

"We can bear 50% of the cost, even the signing fee of the agency contract."

Zhang Yang shook his head and slowly stretched out a finger:

"100%."
 “60%, this is already the most.”

“100%”

"..."

The final proportion talked about 80%.

Novartis bears 80% of the cost of the FDA clinical trial of the "Activator to Promote Liver Cell Regeneration", and this fee is counted as the signing fee for signing the agency contract.

Of course, Friedman is not stupid.

The cost of Phase I clinical trials will not be too high and Novartis can fully afford it.

And in the second phase of clinical trials, as long as it is found that the "activating agent for promoting liver cell regeneration" is not as effective as expected, Novartis can directly abandon the agency contract without losing much.

Zhang Yang is also quite satisfied. As long as the "liver cell regeneration activating agent" wants to be launched in the United States, it will inevitably involve an agency contract. To whom is it not an agent?

Are you not satisfied with an agent who is willing to bear 80% of the cost for you and help you promote FDA clinical trials throughout the entire process?

Both parties in the negotiations between Tsingshan Pharmaceutical and Novartis on "Activating Agents to Promote Liver Cell Regeneration" were quite satisfied, and both parties got the results they wanted.

Early the next morning, after initialing the contract, Novartis obtained a letter of authorization from Qingshan Pharmaceutical and several clinical trial data on the "liver cell regeneration activator". Friedman immediately returned to the United States to start preparing for the FDA Clinical trial matters.

Zhang Yang has completed the signing of the contract with Novartis, and is also focusing on the first-phase clinical approval of the domestic "activating agent that promotes liver cell regeneration".

A week later, the "activating agent that promotes liver cell regeneration" passed the first phase of clinical approval, and 30 patients with liver cirrhosis at Chengcheng Third People's Hospital immediately began a three-month clinical phase one and two trial.

Zhang Yang is very confident in the test results. Although this time the "hepatocyte activator" is not a complete version, the regeneration factor has reached 45%, so...

Once it is long-term Taking it, let alone reversing liver cirrhosis, at least stabilizes the condition of patients with liver cirrhosis and prevents it from getting worse.

After dealing with these things, Zhang Yang finally relaxed and called Ren Xiaomin, Wei Tian and Liu Fei for a hot pot meal that night.

At ten o'clock in the evening, when he returned home, he suddenly discovered that a new node had appeared in the simulator that he had not entered for a long time.

Sit down on the sofa and enter the simulator skillfully. In the void, the name of the new node lights up on the blue light screen:

"Silent Killer."
 Zhang Yang couldn't help but ponder. If the first simulation was a tragedy of blood, it was referring to aplastic anemia.

The second simulation is the fate of a generation, referring to the rampant virus of hepatitis B in this special era.

So what is this silent killer?

After thinking for a while, he shook his head in confusion and simply started the plot simulation directly.

But when he started to recite silently in his mind, a prompt suddenly came from the light screen:

"This node is a limited number of simulation nodes, and the total number of simulations is 5 times."

"Please confirm whether to enable simulation."

Zhang Yang was stunned for a moment, but quickly accepted this method.

He is also someone who has had many simulation experiences, five times is not too few.

"Open."

With a command, as darkness enveloped, several big words slowly appeared in the void:

"All things reincarnate, and humans will live forever." 

"Pharmaceutical Simulation Node 3: Silent Killer!"

"Start!"

(End of this chapter)